Muscle Relaxant Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs, Neuromuscular Blocking Agents), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD3.54 billion

CAGR (2023-2028)

4.45%

Fastest Growing Segment

Retail Pharmacies

Largest Market

North America


Market Overview

Global Muscle Relaxant Drugs Market has valued at USD3.54 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 4.45% through 2028. The global Muscle Relaxant Drugs Market refers to the pharmaceutical industry segment dedicated to the production, distribution, and sale of medications designed to alleviate muscle spasms and tension. These drugs work by targeting the central nervous system or peripheral nerves to reduce muscle contractions and provide relief from conditions such as muscle strains, sprains, and various musculoskeletal disorders.

 Key Market Drivers

The Aging Population and Musculoskeletal Disorders: A Global Health Challenge

The world is undergoing a demographic transformation, with the aging population emerging as a significant global phenomenon. As life expectancy increases and birth rates decline, the proportion of older adults in the global population is steadily rising. With this demographic shift comes a growing concern for age-related health conditions, particularly musculoskeletal disorders. Musculoskeletal disorders encompass a wide range of conditions affecting the bones, joints, muscles, ligaments, and tendons. These disorders can result from factors such as injury, wear and tear, genetic predisposition, and lifestyle choices. As individuals age, their musculoskeletal system undergoes natural changes, making them more susceptible to these conditions. Common musculoskeletal disorders affecting the elderly include osteoarthritis, rheumatoid arthritis, osteoporosis, and back pain. The impact of musculoskeletal disorders on the aging population is substantial and far-reaching. These conditions not only cause pain and discomfort but also limit mobility and independence, leading to a decreased quality of life. Older adults with musculoskeletal disorders may experience difficulty in performing everyday activities, leading to social isolation and a higher risk of depression. Moreover, musculoskeletal disorders pose a considerable economic burden on healthcare systems, as they necessitate frequent medical interventions, hospitalizations, and long-term care. The prevalence of musculoskeletal disorders among the aging population varies across different regions of the world. Factors such as genetics, lifestyle, access to healthcare, and socioeconomic status contribute to these disparities. In developed countries, where life expectancy is higher and healthcare resources are more abundant, the prevalence of musculoskeletal disorders is particularly pronounced. However, developing nations are not immune to this issue, as changing lifestyles and urbanization often lead to increased susceptibility to these conditions. The rising prevalence of musculoskeletal disorders among the aging population poses multifaceted challenges for healthcare systems globally. Firstly, there is an increased demand for specialized medical care, including orthopedic consultations, physical therapy, and surgical interventions. Secondly, healthcare resources must be allocated to provide comprehensive geriatric care, addressing both the physical and psychological aspects of musculoskeletal disorders. Additionally, the need for health education and preventive strategies becomes paramount to reduce the onset and progression of these conditions.

Rising Incidence of Sports Injuries

Sports, both professional and recreational, have long been a source of physical activity, camaraderie, and personal achievement. However, as the world becomes increasingly health-conscious and physically active, the global incidence of sports injuries is on the rise. This trend presents a multifaceted challenge, impacting individuals, communities, and healthcare systems. Sports injuries encompass a wide spectrum of injuries that occur during physical activities, ranging from minor sprains and strains to more severe fractures, ligament tears, and concussions. With the increasing popularity of sports and fitness routines, people of all ages and skill levels are participating in physical activities, making the risk of sports-related injuries more pronounced. More people are engaging in sports and fitness activities, resulting in a larger pool of individuals at risk for injuries. This includes both professional athletes and individuals participating in recreational sports. The drive for excellence and peak performance often pushes athletes to engage in intense training regimens and competitive environments. This heightened level of training can lead to overuse injuries and acute trauma. Inadequate warm-up, poor technique, and insufficient physical conditioning increase the vulnerability to injuries. Proper coaching and training techniques are essential to prevent these injuries. Some athletes focus exclusively on a single sport from a young age, leading to repetitive strain on specific muscles and joints. This specialization increases the risk of overuse injuries. Insufficient rest and recovery periods between training sessions or competitions can result in fatigue, which compromises the body's ability to repair and protect itself from injury.

Increasing Sedentary Lifestyles

In an age defined by technological advancements and modern conveniences, the world is witnessing a significant shift towards sedentary lifestyles. As individuals increasingly spend extended periods sitting at desks, commuting in cars, and engaging with screens, the unintended consequences on physical health are becoming evident. Among these consequences is the rise in musculoskeletal disorders and associated discomfort, driving the demand for muscle relaxant drugs. Sedentary lifestyles are characterized by low levels of physical activity and prolonged periods of sitting or lying down. While technological innovations have undoubtedly enhanced productivity and convenience, they have also fostered an environment that promotes reduced physical movement. The human body, designed for mobility and activity, can suffer adverse effects when subjected to prolonged periods of inactivity. Musculoskeletal strain is one of the most prevalent consequences of sedentary lifestyles. As muscles remain inactive, they can become tense and stiff, leading to discomfort, pain, and the development of musculoskeletal disorders. Common ailments include back pain, neck pain, muscle spasms, and joint stiffness, all of which can significantly impact quality of life. Prolonged sitting can lead to muscle tension and discomfort, prompting individuals to seek relief. Muscle relaxant drugs offer a solution by targeting the central nervous system to alleviate spasms and tension, providing much-needed comfort. Many modern jobs involve sitting for long hours, contributing to the development of musculoskeletal issues. Office workers, computer programmers, and professionals in similar roles may experience chronic discomfort that necessitates the use of muscle relaxant drugs. A sedentary lifestyle often leads to weakened muscles and compromised joint health. When individuals do engage in physical activity, they may be at a higher risk of injuries due to the lack of conditioning, increasing the likelihood of muscle strain and the subsequent need for muscle relaxants. 

 

Download Free Sample Report

Key Market Challenges

Competition from Generic Drugs

As patents for certain muscle relaxant drugs expire, the market faces increased competition from generic drug manufacturers. This competition can lead to price erosion and reduced profit margins for original drug developers. Pharmaceutical companies must navigate this challenge by differentiating their products through innovation, improved formulations, and enhanced therapeutic outcomes.

Misuse and Dependency

Certain muscle relaxant drugs have the potential for misuse and dependency, especially when used for extended periods or in higher doses than prescribed. Managing these risks and ensuring responsible prescribing practices is crucial to avoid contributing to broader societal issues, such as opioid crises.

Patient Compliance and Adherence

Achieving patient compliance and adherence to prescribed muscle relaxant regimens can be challenging. Patients may discontinue treatment prematurely or fail to follow dosage instructions, impacting treatment outcomes. Healthcare professionals and pharmaceutical companies must work together to develop strategies that improve patient understanding and adherence.

Key Market Trends

Biologics and Novel Therapies

The emergence of biologics and novel therapies is reshaping the treatment landscape. Biologics, which are derived from living organisms, offer the potential for targeted interventions with fewer side effects. As research into biologics and advanced therapies progresses, new avenues for addressing musculoskeletal disorders may emerge, providing patients with innovative treatment options.

Ongoing Research and Development

Continued investment in research and development is driving the creation of more effective and safer muscle relaxant drugs. Pharmaceutical companies are exploring novel mechanisms of action, improved delivery systems, and innovative formulations to enhance the therapeutic profile of these medications.

Natural and Herbal Alternatives

A growing interest in natural and herbal alternatives to conventional medications is influencing the Muscle Relaxant Drugs Market. Patients are seeking complementary therapies, such as herbal supplements, essential oils, and holistic approaches, to manage muscle tension and discomfort.

Segmental Insights

Drug Type Insights

In 2022, the global muscle relaxant drugs market was dominated by the skeletal muscle relaxant drugs. Skeletal muscle relaxants were formerly approved for the temporary relief of muscular spasms and back pain, but they are currently used to treat chronic pain and other conditions without proper study. The most common cause for people to visit a doctor is pain. One of the top five reasons for visiting a primary care doctor's office is low back pain. The fastest CAGR growth is projected for neuromuscular blocking drugs during the research period. Neuromuscular blocking medications are often used as muscle relaxants because they can facilitate surgical procedures, hasten endotracheal intubation, and speed up mechanical ventilation by calming skeletal muscles. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Route of Administration Industry Insights

In 2022, the global muscle relaxant drugs market was dominated by oral segment and is injectable segment is predicted to expand over the coming years. Oral form is the most preferred method because of its advantages, such as non-invasiveness, patient compliance, and simplicity of medicine distribution. The market for muscle relaxant medications is predicted to increase at the fastest rate over the forecast period, with injectables leading the pack. The market's leading companies are working to develop cutting-edge injectable products.

 

Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the global muscle relaxant drugs market. In 2022, North America held the highest share of the global market for muscle relaxants. This significant share can be due to the increase in government investment, the rise in chronic disease incidence, and the availability of top-notch infrastructure in the North American region.

Recent Developments

  • The USFDA authorized Zydus Cadila to market Cisatracurium Besylate Injection USP in September 2020 in a 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial strength. The administration of this muscle relaxant comes before general anesthesia.

Key Market Players

  • Amneal Pharmaceuticals LLC
  • Ipsen Biopharmaceuticals Inc
  • Merz Pharmaceuticals LLC
  • Par Pharmaceutical Inc
  • Endo Pharmaceuticals Inc
  • Vertical Pharmaceuticals Inc
  • Mallinckrodt LLC
  • Sterix Ltd
  • Eisai Co Ltd
  • Teva Pharmaceuticals USA Inc

 By Drug Type

  By Distribution Channel

By Route of Administration

By Region
  • Skeletal Muscle Relaxant Drugs
  • Facial Muscle Relaxant Drugs
  • Neuromuscular Blocking Agents
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Oral
  • Injectables
  • Others
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Muscle Relaxant Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Muscle Relaxant Drugs Market, By Drug Type:

o   Skeletal Muscle Relaxant Drugs

o   Facial Muscle Relaxant Drugs

o   Neuromuscular Blocking Agents

  • Muscle Relaxant Drugs Market, By Route of Administration:

o   Oral

o   Injectable

o   Others

  • Muscle Relaxant Drugs Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

  • Uterine Fibroid Treatment Drugs Market, By region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Relaxant Drugs Market.

Available Customizations:

Global Muscle Relaxant Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Muscle Relaxant Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trial Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Application

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Global Muscle Relaxant Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs, Neuromuscular Blocking Agents)

6.2.2.    By Route of Administration (Oral, Injectable, Others)

6.2.3.    By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

6.2.4.    By Region

6.2.5.    By Company (2022)

6.3.  Product Market Map

6.3.1.    By Drug Type

6.3.2.    By Route of Administration

6.3.3.    By Distribution Channel

6.3.4.    By Region

7.    North America Muscle Relaxant Drugs Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Drug Type

7.2.2.    By Route of Administration

7.2.3.    By Distribution Channel

7.2.4.    By Country

7.3.  North America: Country Analysis

7.3.1.    United States Muscle Relaxant Drugs Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Drug Type

7.3.1.2.2.            By Route of Administration

7.3.1.2.3.            By Distribution Channel

7.3.2.    Mexico Muscle Relaxant Drugs Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Drug Type

7.3.2.2.2.            By Route of Administration

7.3.2.2.3.            By Distribution Channel

7.3.3.    Canada Muscle Relaxant Drugs Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.            By Drug Type

7.3.3.2.2.            By Route of Administration

7.3.3.2.3.            By Distribution Channel

8.    Europe Muscle Relaxant Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Drug Type

8.2.2.    By Route of Administration

8.2.3.    By Distribution Channel

8.2.4.    By Country

8.3.  Europe: Country Analysis

8.3.1.    France Muscle Relaxant Drugs Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Drug Type

8.3.1.2.2.            By Route of Administration

8.3.1.2.3.            By Distribution Channel

8.3.2.    Germany Muscle Relaxant Drugs Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Drug Type

8.3.2.2.2.            By Route of Administration

8.3.2.2.3.            By Distribution Channel

8.3.3.    United Kingdom Muscle Relaxant Drugs Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Drug Type

8.3.3.2.2.            By Route of Administration

8.3.3.2.3.            By Distribution Channel

8.3.4.    Italy Muscle Relaxant Drugs Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Drug Type

8.3.4.2.2.            By Route of Administration

8.3.4.2.3.            By Distribution Channel

8.3.5.    Spain Muscle Relaxant Drugs Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Drug Type

8.3.5.2.2.            By Route of Administration

8.3.5.2.3.            By Distribution Channel

9.    Asia-Pacific Muscle Relaxant Drugs Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Drug Type

9.2.2.    By Route of Administration

9.2.3.    By Distribution Channel

9.2.4.    By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.    China Muscle Relaxant Drugs Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Drug Type

9.3.1.2.2.            By Route of Administration

9.3.1.2.3.            By Distribution Channel

9.3.2.    India Muscle Relaxant Drugs Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Drug Type

9.3.2.2.2.            By Route of Administration

9.3.2.2.3.            By Distribution Channel

9.3.3.    South Korea Muscle Relaxant Drugs Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Drug Type

9.3.3.2.2.            By Route of Administration

9.3.3.2.3.            By Distribution Channel

9.3.4.    Japan Muscle Relaxant Drugs Market Outlook

9.3.4.1.        Market Size & Forecast

9.3.4.1.1.            By Value

9.3.4.2.        Market Share & Forecast

9.3.4.2.1.            By Drug Type

9.3.4.2.2.            By Route of Administration

9.3.4.2.3.            By Distribution Channel

9.3.5.    Australia Muscle Relaxant Drugs Market Outlook

9.3.5.1.        Market Size & Forecast

9.3.5.1.1.            By Value

9.3.5.2.        Market Share & Forecast

9.3.5.2.1.            By Drug Type

9.3.5.2.2.            By Route of Administration

9.3.5.2.3.            By Distribution Channel

10.  South America Muscle Relaxant Drugs Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Drug Type

10.2.2. By Route of Administration

10.2.3. By Distribution Channel

10.2.4. By Country

10.3.   South America: Country Analysis

10.3.1. Brazil Muscle Relaxant Drugs Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Drug Type

10.3.1.2.2.         By Route of Administration

10.3.1.2.3.         By Distribution Channel

10.3.2. Argentina Muscle Relaxant Drugs Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Drug Type

10.3.2.2.2.         By Route of Administration

10.3.2.2.3.         By Distribution Channel

10.3.3. Colombia Muscle Relaxant Drugs Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Drug Type

10.3.3.2.2.         By Route of Administration

10.3.3.2.3.         By Distribution Channel

11.  Middle East and Africa Muscle Relaxant Drugs Market Outlook

11.1.   Market Size & Forecast         

11.1.1. By Value

11.2.   Market Share & Forecast

11.2.1. By Drug Type

11.2.2. By Route of Administration

11.2.3. By Distribution Channel 

11.2.4. By Country

11.3.   MEA: Country Analysis

11.3.1. South Africa Muscle Relaxant Drugs Market Outlook

11.3.1.1.     Market Size & Forecast

11.3.1.1.1.         By Value

11.3.1.2.     Market Share & Forecast

11.3.1.2.1.         By Drug Type

11.3.1.2.2.         By Route of Administration

11.3.1.2.3.         By Distribution Channel

11.3.2. Saudi Arabia Muscle Relaxant Drugs Market Outlook

11.3.2.1.     Market Size & Forecast

11.3.2.1.1.         By Value

11.3.2.2.     Market Share & Forecast

11.3.2.2.1.         By Drug Type

11.3.2.2.2.         By Route of Administration

11.3.2.2.3.         By Distribution Channel

11.3.3. UAE Muscle Relaxant Drugs Market Outlook

11.3.3.1.     Market Size & Forecast

11.3.3.1.1.         By Value

11.3.3.2.     Market Share & Forecast

11.3.3.2.1.         By Drug Type

11.3.3.2.2.         By Route of Administration

11.3.3.2.3.         By Distribution Channel

11.3.4. Kuwait Muscle Relaxant Drugs Market Outlook

11.3.4.1.     Market Size & Forecast

11.3.4.1.1.         By Value

11.3.4.2.     Market Share & Forecast

11.3.4.2.1.         By Drug Type

11.3.4.2.2.         By Route of Administration

11.3.4.2.3.         By Distribution Channel

12.  Market Dynamics

12.1.   Drivers

12.2.   Challenges

13.  Market Trends & Developments

13.1.   Recent Developments

13.2.   Product Launches

13.3.   Mergers & Acquisitions

14.  Policy & Regulatory Landscape

15.  Porter’s Five Forces Analysis

15.1.   Competition in the Industry

15.2.   Potential of New Entrants

15.3.   Power of Suppliers

15.4.   Power of Customers

15.5.   Threat of Substitute Product

16.  Competitive Landscape

16.1.   Business Overview

16.2.   Company Snapshot

16.3.   Products & Services

16.4.   Financials (In case of listed companies)

16.5.   Recent Developments

16.6.   SWOT Analysis

16.6.1. Amneal Pharmaceuticals LLC

16.6.2. Ipsen Biopharmaceuticals Inc

16.6.3. Merz Pharmaceuticals LLC

16.6.4. Par Pharmaceutical Inc

16.6.5. Endo Pharmaceuticals Inc

16.6.6. Vertical Pharmaceuticals Inc

16.6.7. Mallinckrodt LLC

16.6.8. Sterix Ltd

16.6.9. Eisai Co Ltd

16.6.10.                Teva Pharmaceuticals USA Inc

17.  Strategic Recommendations

18.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Muscle Relaxant Drugs Market was estimated to be USD3.54 billion in 2022.

down-arrow

Amneal Pharmaceuticals LLC, Ipsen Biopharmaceuticals Inc, Merz Pharmaceuticals LLC, Par Pharmaceutical Inc, Endo Pharmaceuticals Inc, Vertical Pharmaceuticals Inc , Mallinckrodt LLC, Sterix Ltd, Eisai Co Ltd, Teva Pharmaceuticals USA Inc are some of the key players operating in the Global Muscle Relaxant Drugs Market.

down-arrow

Regulatory scrutiny and safety concerns, side effects and patient concerns, competition from generic drugs are some of the major challenges faced by the Global Muscle Relaxant Drugs Market in the upcoming years.

down-arrow

Advancements in medical research and technology, awareness, and diagnosis of musculoskeletal conditions, evolving regulatory environment amongst others are majorly driving the demand for the global Muscle Relaxant Drugs market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Muscle Relaxant Drugs Market to Grow with a CAGR of 4.45% through 2028

Oct, 2023

Investment of pharmaceutical companies in innovative formulations are the major drivers for the Global Muscle Relaxant Drugs Market.

Why Choose Us